News | November 02, 2012

Stereotactic Radiosurgery Shows Promise for Kidney Cancer

Data presented by University Hospitals Case Medical Center researchers at ASTRO 2012

November 2, 2012 — A first-of-its-kind clinical trial conducted at University Hospitals (UH) Case Medical Center Seidman Cancer Center has shown encouraging results for the use of stereotactic radiosurgery to treat kidney cancer. This noninvasive treatment technique may represent a potential new nonsurgical option for patients with the disease who have limited treatment options.

Rod Ellis, M.D., lead author of the study along with principal investigator Lee Ponsky, M.D., presented results of a phase I clinical trial in 20 patients with localized primary renal cancer at the American Society for Radiation Oncology (ASTRO) annual meeting in Boston. In the abstract titled "Stereotactic Radiosurgery for Renal Cancer: Phase I Safety and Toxicity," Ellis presented data showing that 94 percent of patients treated in the study had decreased or stable disease, with limited side effects.

"This trial shows that low to moderate doses of stereotactic radiosurgery are safe for renal cancer patients who typically do not have surgical options," said Ellis, clinical director and vice chair for clinical affairs, department of radiation oncology at UH Case Medical Center, and associate professor of radiation oncology and urology at Case Western Reserve University School of Medicine. "Based on these findings, this treatment represents a promising therapeutic option. Further studies are needed to determine safe levels for the maximum dosage and by doing so, we hope to find increased response and cure rates with this method."

"This study is a unique partnership between a surgeon and radiation oncologist, intended to offer patients a noninvasive, highly focused ablative radiation with surgical precision with little to no side effects," said Ponsky, director of urologic oncology and minimally invasive therapies at UH Case Medial Center, and associate professor of urology at Case Western Reserve School of Medicine. "We are very excited about these results and cautiously optimistic about the future potential of this therapy."

According to the American Cancer Society, there are about 65,000 new cases of kidney cancer each year in the United States, and it is among the 10 most common cancers in both men and women. Treatment options typically include surgery or cryoablation (using cold therapy to destroy the tumor). However, many patients are not surgical candidates, and stereotactic radiosurgery provides a noninvasive alternative in just three treatments which requires no anesthesia or narcotics. Stereotactic radiosurgery is performed using Cyberknife, a robotic radiosurgery system which delivers targeted doses of radiation with submillimeter accuracy while minimizing damage to surrounding healthy tissue. This high-dose, focused radiation destroys tumor cells and stops cancer cells from growing.

This study followed patients from two to 41 months post-treatment using a four-part dose escalation schema. The response rate indicates that patients reacted well and had acceptable levels of treatment-related toxicity following stereotactic radiosurgery in all age groups from 58 to 92 years old.

Based on these positive results, Ellis, Ponsky and a team of researchers have launched a follow-up phase II study for 12 additional patients with increased dosage to determine the most effective dosage. "This study builds upon our team's previous work as we continue to evaluate and define the role of radiosurgery for the safe and effective treatment of kidney tumors," said Ponsky.

"Radiosurgery delivers a higher and more effective dose directly to the tumor site with less side effects than conventional radiation and has been very effective in treating other hard-to-reach tumors," said Ellis. "We are excited about its potential for kidney cancer patients and to be able to offer a noninvasive option."

Study co-authors include R.B. Patel, C. Kunos, Y. Zhang, J. Brindle, V. Kudithipudi and D.A. Kaminsky. The trial funded by Accuray Corp.

For more information: www.uhhospitals.org

Related Content

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound
News | Focused Ultrasound Therapy | August 22, 2017
Insightec announced recently that worldwide adoption of magnetic resonance (MR)-guided focused ultrasound continues to...
UCLA Study Offers Roadmap to Personalized Therapies for Sarcoma
News | Oncology Diagnostics | August 22, 2017
A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of...
Sponsored Content | Videos | Information Technology | August 22, 2017
Melissa Martin, MS, president of the American Association of Physicists in Medicine (AAPM), discusses her vision of t
Comparison of Screening Recommendations Supports Annual Mammography
News | Mammography | August 22, 2017
When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue...
Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | August 21, 2017
Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact...
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
Overlay Init